Page 32 - CIBEREHD-2015-eng

Platforms
E-CATCH. Diagnosis and Treatment of Liver Cancer
The e-CATCH platform aims to provide diagnostic and therapeutic guidance services by electronic consultation for patients with liver cancer. The pos- sibility of evaluating both reports and imaging tech- niques enables consulting doctors to reliably review the information available and provides guidance based on scientific evidence. In 2015 a contract was established with pharmaceutical company Bayer which financed the telemedicine work.
In 2015 over 50 consultations were made over the platform and its review has been started in order to offer consultation services internationally and thus ensure the sustainability of the platform.
As well as the consultancy services the platform has enabled transferring tomography or resonance images in order to validate the results of multi-cen- tre studies and thus guarantee the validity of the readings of images by independent radiologists.
HEPA-C. National Database for Patients with chronic Hepatitis C
Hepa-C is a cooperation project which in 2015 en- abled storing the data of 3000 patients infected with hepatitis C undergoing treatment in real clini- cal practice with direct-acting antivirals, most of which were interferon-free. Its design has enabled a compilation of all the variables needed to carry out high quality research projects. The information has been monitored and is thus much more reliable than other well-known collaborative registers, in turn pro- viding technical assistance for the participants. In 2015 60 attached centres had joined the scheme, most of them taking an active part. The information contained in Hepa-C has enabled the presentation of several works at the XL congress of the AEEH and at the International Liver Congress of the EASL:
• Poster No 92: The season of the year in which tri- ple therapy starts predicts fast viral response in patients with the hepatitis C virus (VHC) genotype 1: Analysis of the Hepa-C register.
• Oral communication: First data on real clinical practice in Spain with Sofosbuvir, Simeprevir and Daclatasvir in patients with HCV infection: experi- ence of the Hepa-C registry.
• Oral communication: first data on clinical practice in Spain through compassionate use of Sofosbu- vir, Simeprevir and Daclatasvir in transplanted patients with recurrent HCV: experience of the Hepa-C register.
• Poster No 0785: First real clinical practice data in Spain on Sofosbuvir, Simeprevir and Daclatasvir in post-transplant HCV recurrence: the Hepa-C Registry Experience.
• Poster No 0862: First real clinical practice data on Sofosbuvir, Simeprevir and Daclatasvir with HCV-Chronically infected patients in Spain: the Hepa-C Registry Experience.
Two manuscripts were also approved for sending to high-impact journals (pending acceptance) and a large number of communications were sent for the coming congresses of the AEEH/ EASL in 2016, with many posters and oral communications already having been accepted to be given in the coming year.
32 I Annual report 2015 I CIBEREHD